Biologix is a Dubai-based firm that represents international pharma companies by bringing innovative drugs to market in the Middle East / North Africa (MENA) region. Its GM, Zeina Sfeir Lahoud, discusses the company’s presence in over 17 countries, their 25 years of experience in Saudi Arabia, and the dynamics shaping the largest market in the region, including the fast regulatory approval process in place. With value-based healthcare an increasingly hot topic, she explains how Biologix has moved to sign the first risk-sharing agreement with Saudi Arabia for a spinal muscular atrophy product; the first in the MENA region.
STAY UP TO DATE NEWS & EVENTS
Related EVENTS & NEWS
Biologix Attends Middle East Pharmacoeconomics and Drug Policy Summit in Dubai
On April 28th and 29th 2023, Biologix team attended the Middle East Pharmacoeconomics and Drug Policy Summit in Dubai.
Medical Affairs Department Participates in 3rd Kuwait Pediatric Stem Cell Transplant and Cellular Therapy Congress
The Medical Affairs Department has participated in the 3rd Kuwait Pediatric Stem Cell Transplant and Cellular Therapy Congress that took place on January 23rd and 24th, 2024, at the Four Seasons Hotel in Kuwait.
Biologix at the International Pediatric Summit 2024
Biologix provided significant insights in the management of allergic and nephropathic cystinosis patients by sponsoring a medical symposium titled "Twice Daily Triumph: Simplifying Nephropathic Cystinosis Treatment" at the International Pediatric Summit – Revolutionary Edition IPS 2024 in Dubai.
